language-icon Old Web
English
Sign In
Acemap > Paper > HER2 overexpression predicts survival in stage II and III breast cancer patients treated with neoadjuvant docetaxel plus epirubicin

HER2 overexpression predicts survival in stage II and III breast cancer patients treated with neoadjuvant docetaxel plus epirubicin

2005 
Keywords:
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []
    logo
    • CCF Conference Analysis
    • Map Galaxy
    • What's New
    © Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.